One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
OrganiGram Holdings  logo
OrganiGram Holdings OGI
$ 0.94 0.38%
report update icon

Quarterly report 2024-Q4
added 10-15-2026

OrganiGram Holdings Balance Sheet 2024-2011 | OGI

Brief balance sheet overview of OrganiGram Holdings

The comparison uses five available annual reports from the 2020–2024 interval.

Across five reporting periods, assets decreased -6.3%, from 435.1 million CAD to 407.9 million CAD, producing a negative trend.

Liability growth of -24.9% trailed asset growth of -6.3%. The funding structure became more resilient.

Equity accounts for 75% of assets. Against the initial 68.8%, the capital position looks resilient.

The balance sheet holds more cash than interest-bearing debt; net debt is -102.4 million CAD, indicating minimal leverage.

Cash represents 26.2% of assets versus 5.7% initially, showing how the immediate liquidity reserve changed.

The balance sheet carries negative retained earnings of -584 million CAD. The figure may result from accumulated losses or an active capital return policy.

Overall assessment

OrganiGram Holdings 's balance sheet looks resilient: assets are supported by substantial equity, while debt does not overwhelm financial flexibility.

Annual Balance Sheet OrganiGram Holdings

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-102 M -29.3 M -65.4 M - 90.7 M 2.02 M 44.1 M 1.56 M -2.37 M 3.39 M -137 K -158 K -321 K -

Long Term Debt

3.34 M 3.55 M 2.21 M - 104 M 46.1 M 98.7 M 3.13 M 7.16 M 4.57 M - - - -

Long Term Debt Current

1.03 M 1.01 M 916 K 984 K 1.09 M - - - - - - - - -

Total Non Current Liabilities

- - - - 107 M 57.7 M 107 M 3.13 M 7.16 M 4.57 M - - - -

Total Liabilities

102 M 26.8 M 69 M 74.2 M 136 M 102 M 118 M 9.78 M 9.61 M 6.32 M 115 K 73 K 39.6 K -

Retained Earnings

-584 M -539 M -290 M - -145 M -8.78 M 759 K -19.8 M -8.87 M -9.71 M -833 K -594 K -219 K -

Total Assets

408 M 298 M 577 M 554 M 435 M 429 M 303 M 92.8 M 53.9 M 14.2 M 140 K 337 K 501 K -

Cash and Cash Equivalents

107 M 33.9 M 68.5 M - 24.6 M 47.6 M 55.1 M - - - - - - -

Book Value

306 M 272 M 508 M 480 M 300 M 327 M 185 M 83 M 44.3 M 7.85 M 24.5 K 264 K 462 K -

Total Shareholders Equity

306 M 272 M 508 M - 300 M 327 M 185 M - - - - - - -

All numbers in CAD currency

Quarterly Balance Sheet OrganiGram Holdings

2024-Q4 2024-Q3 2023-Q4 2023-Q3 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

3.55 M 3.34 M 2.21 M 3.55 M - - - - - 4.65 M - - - 2.62 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - - - - - - - - - - - - 102 M - - - 118 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

26.8 M 102 M 69 M 26.8 M - - - - - 74.2 M - - - 136 M - - - 102 M - - - 118 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-539 M -584 M -290 M -539 M - - - - - -276 M - - - -145 M - - - -8.78 M - - - 759 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

298 M 408 M 577 M 298 M - - - - - 554 M - - - 435 M - - - 429 M - - - 303 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

68.5 M 107 M 55.4 M 33.9 M - - - - - 55.4 M - - - 24.6 M - - - 47.6 M - - - 55.1 M - - - 1.96 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

272 M 306 M 508 M 272 M - - - - - 480 M - - - 300 M - - - 327 M - - - 185 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

508 M 306 M 480 M 272 M - - - - - 480 M - - - 300 M - - - 327 M - - - 185 M - - - 82.9 M - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in CAD currency

Balance Sheet is a fundamental financial report of OrganiGram Holdings , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Drug manufacturers

Issuer Price % 24h Market Cap Country
Perrigo Company plc Perrigo Company plc
PRGO
$ 15.91 -1.64 % $ 2.2 B usaUSA
Cumberland Pharmaceuticals Cumberland Pharmaceuticals
CPIX
$ 8.17 2.64 % $ 121 M usaUSA
Evolus Evolus
EOLS
$ 7.4 0.41 % $ 477 M usaUSA
Tricida Tricida
TCDA
- - $ 3.25 M usaUSA
Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc
AVDL
- - $ 2.06 B franceFrance
DURECT Corporation DURECT Corporation
DRRX
- - $ 50.1 M usaUSA
Aerie Pharmaceuticals Aerie Pharmaceuticals
AERI
- - $ 754 M usaUSA
Endo International plc Endo International plc
ENDP
- - $ 28.9 M irlandaIrlanda
Radius Health Radius Health
RDUS
- - $ 1.42 B usaUSA
Recro Pharma Recro Pharma
REPH
- -4.76 % $ 65.3 M usaUSA
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation
ADMP
- 0.86 % $ 117 M usaUSA
Agile Therapeutics Agile Therapeutics
AGRX
- 10.11 % $ 58.2 M usaUSA
Evoke Pharma Evoke Pharma
EVOK
- - $ 36.6 M usaUSA
Alimera Sciences Alimera Sciences
ALIM
- - $ 142 M usaUSA
PLx Pharma PLx Pharma
PLXP
- -27.8 % $ 2.56 M usaUSA
Athenex Athenex
ATNX
- -23.39 % $ 1.76 M usaUSA
Lannett Company Lannett Company
LCI
- 1.15 % $ 7.11 M usaUSA
Zynerba Pharmaceuticals Zynerba Pharmaceuticals
ZYNE
- - $ 55.5 M usaUSA
Aurora Cannabis Aurora Cannabis
ACB
$ 3.96 -0.25 % $ 217 M canadaCanada
Catalent Catalent
CTLT
- - $ 11.5 B usaUSA
Eagle Pharmaceuticals Eagle Pharmaceuticals
EGRX
- -39.89 % $ 27.7 M usaUSA
OptiNose OptiNose
OPTN
- - $ 1.08 B usaUSA
Emergent BioSolutions Emergent BioSolutions
EBS
$ 6.2 -1.43 % $ 332 M usaUSA
PetIQ PetIQ
PETQ
- 1.64 % $ 400 M usaUSA
Pacira BioSciences Pacira BioSciences
PCRX
$ 36.33 -0.14 % $ 1.62 B usaUSA
Rockwell Medical Rockwell Medical
RMTI
$ 7.08 -2.07 % $ 255 M usaUSA
Solid Biosciences Solid Biosciences
SLDB
$ 6.41 0.16 % $ 561 M usaUSA
Tilray Tilray
TLRY
$ 2.92 -3.63 % $ 327 M canadaCanada
TherapeuticsMD TherapeuticsMD
TXMD
$ 1.9 1.06 % $ 22 M usaUSA
Veru Veru
VERU
$ 2.3 -3.36 % $ 33.7 M usaUSA
Viatris Viatris
VTRS
$ 18.45 -1.07 % $ 21.2 B usaUSA
Harrow Health Harrow Health
HROW
$ 28.24 0.61 % $ 1.04 B usaUSA
Canopy Growth Corporation Canopy Growth Corporation
CGC
$ 0.67 -6.67 % $ 200 M canadaCanada
Organogenesis Holdings Organogenesis Holdings
ORGO
$ 0.99 -2.81 % $ 125 M usaUSA
SCYNEXIS SCYNEXIS
SCYX
$ 3.79 -0.39 % $ 189 M usaUSA
Sundial Growers Sundial Growers
SNDL
$ 1.28 0.39 % $ 330 M canadaCanada
Sonoma Pharmaceuticals Sonoma Pharmaceuticals
SNOA
$ 1.14 -0.87 % $ 1.92 M usaUSA
cbdMD cbdMD
YCBD
$ 0.38 -2.14 % $ 1.53 M usaUSA
Bausch Health Companies Bausch Health Companies
BHC
$ 6.45 0.55 % $ 2.39 B canadaCanada
Cronos Group Cronos Group
CRON
$ 3.39 3.35 % $ 1.3 B canadaCanada
China Pharma Holdings China Pharma Holdings
CPHI
$ 0.7 -3.78 % $ 3 M chinaChina
Relmada Therapeutics Relmada Therapeutics
RLMD
$ 3.21 -4.46 % $ 127 M usaUSA
HEXO Corp. HEXO Corp.
HEXO
- 2.45 % $ 38.1 M canadaCanada
Calliditas Therapeutics AB (publ) Calliditas Therapeutics AB (publ)
CALT
- -0.1 % $ 2.03 B schwedenSchweden
AcelRx Pharmaceuticals AcelRx Pharmaceuticals
ACRX
- 7.5 % $ 6.35 M usaUSA
Assertio Holdings Assertio Holdings
ASRT
- - $ 150 M usaUSA
Jupiter Wellness Jupiter Wellness
JUPW
- - $ 33.6 M usaUSA
Neoleukin Therapeutics Neoleukin Therapeutics
NLTX
- - $ 193 M canadaCanada
ProPhase Labs ProPhase Labs
PRPH
- - $ 5.07 M usaUSA